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Abstract
Background Transoral treatment of gastroesophageal
reﬂux disease (GERD) using the EsophyX device enables
creation of an esophagogastric fundoplication with poten-
tial for better control of reﬂux than gastrogastric tech-
niques. Efﬁcacy and safety of a rotational/longitudinal
esophagogastric transoral incisionless fundoplication (TIF)
was evaluated retrospectively using subjective and objec-
tive outcomes.
Methods Thirty-seven consecutive patients on antisecre-
tory medication and with proven gastroesophageal reﬂux
and limited hiatal hernia underwent TIF for persistent
GERD symptoms. Five patients were reoperations for
failed laparoscopic fundoplication.
Results Of the 37 treated patients, 57% were female. The
median age was 58 (range = 20–81) years and BMI was
25.5 (range = 15.9–36.1) kg/m
2. Sixty-eight percent indi-
cated GERD-associated cough, asthma, or aspiration as a
primary complaint and 32% complained of heartburn or
regurgitation. The TIF procedures created tight wraps of
230–330 extending 3–4 cm above the Z-line. Two com-
plications occurred: one mediastinal abscess treated lapa-
roscopically and one postoperative bleeding requiring
transfusion. At 6 (range = 3–14) months median follow-up
TIF resulted in a signiﬁcant improvement of both atypical
and typical symptoms in 64% and 70–80% of patients,
respectively, as indicated by the corresponding GERD
health-related quality of life (HRQL) and reﬂux symptom
index (RSI) score reduction by 50% or more compared to
baseline on proton pump inhibitors (PPIs). No patient
reported problems with dysphagia, bloating, or excess ﬂat-
ulence, and 82% were not taking any PPIs. Reﬂux charac-
teristics were signiﬁcantly improved and normalized in 61,
89,and56%ofpatients intermsofacidexposure,numberof
reﬂuxates, and DeMeester scores, respectively. TIF was
effective in treating GERD in 75% of patients among whom
54% were in a complete ‘‘remission’’ and 21% were
‘‘improved.’’ The remaining 25% were considered failures,
and ﬁve (13.5%) patients underwent revision.
Conclusion Rotational/longitudinal esophagogastric fun-
doplication using the EsophyX device signiﬁcantly
improved symptomatic and objective outcomes in over
70% of patients at median 6-month follow-up. Post-fun-
doplication side effects were not reported after TIF.
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Gastroesophageal reﬂux disease (GERD) is one of the
most common clinical disorders observed in developed
countries. In the US, nearly 20% of the adult population
experiences typical GERD symptoms such as heartburn or
acid regurgitation at least once a week, with an annual
prevalence reaching 60% [1]. Traditional treatment has
been medical (mainly proton pump inhibitors, PPIs), with
surgery reserved for patients with incomplete symptom
control or intolerance to medical therapy [2]. In recent
years, however, there has been a growing number of
reports suggesting that approximately 30% (range =
25–40%) of GERD patients do not obtain symptomatic
relief (either partially or completely) on standard-dose PPI
therapy [3–6]. Medical therapy also appears to have lim-
ited effectiveness in 30–50% of GERD patients with
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continue to experience hoarseness, sore or burning throat,
chronic cough, or excessive throat-clearing despite nor-
malized esophageal acid exposure on aggressive PPI
therapy [7, 8]. Studies comparing groups of patients with
primarily typical or atypical GERD symptoms have found
the same degree of distortion and deterioration of the
esophagogastric junction, suggesting a similar pathophys-
iology [9–11]. This anatomic similarity together with the
refractory nature of symptoms establishes surgical fundo-
plication as appropriate therapy in patients with estab-
lished GERD and laryngeal symptoms [12, 13].
Antireﬂux surgery is a well-established surgical proce-
dure in preventing both acid and nonacid reﬂux and is
known to be effective in patients with both typical (heart-
burn and regurgitation) and atypical GERD symptoms
[12–15]. Antireﬂux surgery recreates a competent gastro-
esophageal valve and reduces or eliminates reﬂux. Even
though now performed laparoscopically, surgery creates in
some patients a super-competent gastroesophageal valve
that leads to new side effects of bloating, ﬂatulence, and
diarrhea in a small percentage of patients [16]. In addition,
traditional surgical techniques were developed to correct
severe anatomic defects, including large hiatal hernias, and
may be more than needed in patients with less severe
anatomic defects that still suffer from GERD. Division of
the phrenoesophageal membranes in the performance of
laparoscopic fundoplication creates a potential for trans-
thoracic wrap migration, with its attendant morbidity, even
in patients whose phrenoesophageal membranes are still
relatively intact.
Attempts at transoral fundoplication to treat gastro-
esophageal reﬂux have until recently been limited to
gastrogastric plications and generated reasonable clinical
outcomes [17–20]. The EsophyX device provides the
potential to perform a transoral esophagogastric fundopli-
cation. Polypropylene fasteners are placed between the
esophageal lumen and the gastric cardia up to 4 cm above
the Z-line to create a fundoplication of over 270 in cir-
cumference as visualized endoscopically. This newer
technique combines rotational and longitudinal plications
to create esophagogastric fundoplication and has the
potential for improved control of reﬂux compared to purely
longitudinal esophagogastric or gastrogastric plication.
The purpose of this retrospective single-institution,
single-surgeon study was to evaluate the efﬁcacy and
safety of this esophagogastric transoral incisionless fun-
doplication (TIF) technique using the EsophyX
 device
(EndoGastric Solutions, Redmond, WA). Patients who
have already had the TIF procedure to treat established
GERD were evaluated with appropriate outcome ques-
tionnaires along with objective studies including the use of
ambulatory pH testing.
Patients and methods
Patients
After obtaining approval from the HCA-HealthOne Insti-
tutional Review Board in October 2009, 37 consecutive
patients who underwent TIF at our institution between
November 2008 and October 2009 were asked to consent
to a retrospective evaluation of their clinical course and a
follow-up visit at 6 or 12 months for upper GI endoscopy
and 48-h telemetry capsule pH testing. One patient was
excluded from follow-up analysis due to an early operation
for a complication that resulted in takedown of the TIF and
creation of a laparoscopic fundoplication (see Safety Out-
comes below.)
Patients underwent TIF because they had persistent
typical or atypical GERD symptoms on daily antisecretory
medication (response \80%), proven gastroesophageal
reﬂux by either 24-h pH/impedance, 48-h pH, or barium
swallow testing, and a deteriorated gastroesophageal
junction (Hill grade II or III [21]) on endoscopy. Five were
reoperations after failed Nissen (n = 4) or Toupet
fundoplication.
Preoperative assessment
The preoperative evaluation of TIF patients followed our
routine protocol for surgical fundoplication patients [22].
The protocol involved a complete history and physical,
symptom severity evaluation using two standardized
questionnaires, upper GI endoscopy, and gastroesophageal
reﬂux evaluation by barium swallow, reﬂux measurement
by either 48-h telemetry capsule pH monitoring or 24-h
impedance/pH testing, and esophageal manometry. Symp-
toms were evaluated using the Reﬂux Symptom Index
(RSI) for LPR symptoms [23] and GERD Health-related
Quality of Life (GERD-HRQL) for typical GERD symp-
toms [24].
The TIF procedure was considered an appropriate
alternative to laparoscopic fundoplication when the axial
height of the hiatal hernia was less than or equal to 2 cm,
the transverse dimensions of the hiatal hernia did not
exceed 3 cm, and the patient was willing to abide by
postoperative recommendations related to diet and physical
activity.
TIF technique
Our rotational/longitudinal esophagogastric TIF technique,
including preoperative and postoperative surgical care, has
been described in detail previously [25]. The rotational
element of the procedure, along with the degree to which
the plication is placed above the Z-line, differs from the
1976 Surg Endosc (2011) 25:1975–1984
123techniques described initially [17, 19, 20, 26, 27]. Brieﬂy,
under general anesthetic, the EsophyX device is introduced
over a ﬂexible endoscope into the stomach. With the
endoscope retroﬂexed for visualization, the device’s tissue
mold is retroﬂexed. From the apex of the device a helical
retractor is advanced into the Z-line at the lesser curvature.
With caudal retraction on the helical retractor, the tissue
mold is used to rotate the fundus up and around the
esophagus. The tissue mold and helix are locked in place,
and polypropylene H-shaped fasteners are deployed above
the Z-line so that one leg of the H engages in the esoph-
ageal wall and the other in the gastric lumen (Fig. 1). This
procedure is repeated at various rotational positions and
longitudinal depths until 12–20 fasteners are deployed.
This results in an esophagogastric plication that extends
above the Z-line for 3–4 cm and circumferentially for more
than 270 (Fig. 1).
Postoperative stay was typically 1 day as was duration
of IV pain medication. Patients were asked to follow a
liquid diet for the ﬁrst 2 weeks a soft diet for another
2 weeks and to resume a normal diet 4 weeks post proce-
dure. All patients continued on antisecretory medication for
2 weeks after the procedure to minimize the potential for
gastric bleeding and then stopped their antisecretory med-
ication. Patients were also asked to refrain from vigorous
exercise for 4 weeks.
Follow-up assessment
Patients were seen at 1 week and again at 1 month,
3 months, and then every 6 months postoperatively.
Patients unwilling to come to the clinic at 1 or 3 months
were followed up by mailed questionnaire and telephone. A
complete evaluation was conducted at 6 or 12 months and
consisted of symptom evaluation (HRQL, RSI), endoscopy,
and a 48-h pH test using a telemetry capsule pH monitoring
system (Bravo, Given Imaging, Duluth, GA) after
discontinuation of acid-suppressive medication for a min-
imum of 7 days. Patients experiencing symptom recurrence
before the 6-month follow-up underwent a complete
objective evaluation with endoscopy and pH testing to
determine the reasons for failure and the need for TIF or
Nissen revision.
Effectiveness assessment
The primary effectiveness measure was symptom elimi-
nation based on RSI and GERD-HRQL score reduction at
follow-up compared to baseline on PPIs. The RSI is a nine-
item questionnaire developed and validated to measure
symptoms associated with laryngopharyngeal reﬂux (LPR)
such as hoarseness, throat-clearing, excess throat mucus,
dysphagia, and cough [23]. A visual analog scale (VAS) for
each individual item ranges from 0 (no problem) to 5
(severe problem), with a maximum total score of 45 and
normality threshold of B13. The GERD-HRQL is a vali-
dated disease-speciﬁc questionnaire measuring the severity
of heartburn (six questions), dysphagia (two), bloating
(one), and the impact of medication on daily life (one) on
the VAS scale from 0 (no symptoms) to 5 (worst symp-
toms) [24, 28]. Scores of B2 to each question are indicative
of rare or eliminated symptoms [12]. The last item of the
questionnaire evaluates the patient’s general satisfaction
with his/her current health condition as ‘‘satisﬁed,’’ ‘‘neu-
tral,’’ or ‘‘dissatisﬁed.’’ Total GERD-HRQL scores are
calculated by summing the responses to ten questions. The
same six questions as those assessing heartburn were used
to assess regurgitation scores. A clinically signiﬁcant
improvement was deﬁned in the protocol as a 50% or more
reduction in scores at follow-up compared to baseline on
PPIs.
Secondary effectiveness measures were normal esoph-
ageal acid exposure, PPI discontinuation, hiatal hernia
reduction, and Hill grade normalization. Follow-up pH
Fig. 1 Schematic drawings of
the esophagogastric transoral
incisionless fundoplication
(TIF) technique with a depiction
of fastener placement and the
plications obtained. Left
Fasteners (blue) are placed
caudally to the diaphragm but
still above the Z-line (left
panel). Right Retroﬂex view of
the esophagogastric plications
extending circumferentially for
more than 270 with external
relationship to the aorta, vena
cava, liver, and spleen
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123testing was performed using a 48-h telemetry capsule pH
monitoring system. Subjects were asked to maintain their
normal eating and daily activity patterns as well as record
timing of their meals, sleep, and symptoms. Each pH-
tracing was examined and considered valid if there was at
least 16 h of recording for each 24-h period of monitoring.
Esophageal acid exposure corresponded to the percentage
of total monitoring time at pH\4 and was deﬁned as
normal if pH B 5.3% while off PPIs [29, 30]. A mean
number of reﬂux episodes of 44 or fewer per 24 h and
DeMeester score of B14.72 while off PPIs were each
considered normal values [31, 32]. Esophageal acid expo-
sure was considered normalized if preoperative values
were pathologic. The use of PPIs and other GERD medi-
cations was recorded. A complete discontinuation of PPIs
was considered clinically signiﬁcant.
A global assessment of all outcome measures was per-
formed for each patient to determine the effectiveness of
TIF in curing GERD [17]. Patients were considered ‘‘in
remission’’ if they had no more atypical and typical
symptoms, used no PPIs, were satisﬁed with the condition
of their health, and had normalized reﬂux parameters.
Patients were considered ‘‘improved’’ if they had fewer
typical or atypical symptoms, required no PPIs, were sat-
isﬁed with the condition of their health, and had normal-
ized or improved at least one reﬂux parameter. Patients
with ‘‘ongoing’’ GERD showed no alleviation of their
typical and atypical symptoms, required daily PPIs, were
not satisﬁed with the condition of their health, and had
abnormal pH-metry.
Upper GI endoscopy was performed to assess hiatal
hernia length (deﬁned as the distance from the Z-line to
diaphragmatic pinch measured in centimeters at retraction
of the endoscope without insufﬂation), reﬂux esophagitis
grade according to the Los Angeles classiﬁcation [33], and
the geometric aspects of the TIF valves such as length,
circumference, and Hill grade [17].
The incidences of anticipated and unanticipated serious
and nonserious adverse events were recorded and used for
safety assessment.
Statistical methods
Data were collected prospectively using a computerized
database (Microsoft Access, Microsoft, Redmond, WA).
Statistical analysis was performed using Minitab 15
statistical software (Minitab Inc., State College, PA).
Continuous variables were summarized as means and
standard deviations (SD) or standard errors (SEM), or
medians and ranges. Categorical variables were summa-
rized as counts and percentages. P values for changes at
follow-up compared to those at baseline were calculated
using the Mann–Whitney U and paired t tests. Fisher’s
exact test was used to compare frequencies. Values of
p\0.05 were considered signiﬁcant.
Results
Patient characteristics at baseline
The median age of the 37 treated patients was 58
(range = 20–81) years, 21 (57%) were female, and 35
(95%) had BMI\35 kg/m
2 (Table 1). All patients had a
long history of GERD treated with PPI therapy, which was
ineffective in controlling symptoms in 92%. The majority
of patients (n = 25, 68%) presented with an atypical
GERD symptom: chronic cough or chest pain related to
cough (n = 15, 41%), asthma (n = 4, 11%), aspiration
(n = 2, 5%), hoarseness and vocal cord problems (n = 2,
5%), or chronic sinusitis (n = 2, 5%). All patients with
atypical symptoms reported no or partial (\80%) response
to PPIs, 88% (15/17) had abnormal RSI scores (Fig. 2), and
40% (10/25) complained also of secondary heartburn or
regurgitation, both of which were refractory to PPIs in 70%
of the cases. An otolaryngologist or pulmonologist ruled
out other diagnoses and conﬁrmed the diagnosis of laryn-
gopharyngeal reﬂux in all patients with a primary com-
plaint of LPR. Among patients with primarily typical
symptoms (n = 11), 60% reported also atypical symptoms
as a secondary complaint. Upper abdominal bloating/dis-
tention and excess of ﬂatulence were reported by 68% of
patients. Twelve patients (33%) had reducible 2-cm-long
hiatal hernia, which was accompanied by reﬂux esophagitis
in three (9%) patients (Table 1); the remaining 24 (67%)
patients did not have a visible hiatal hernia.
Table 1 Patient characteristics at the time of esophagogastric trans-
oral incisionless fundoplication (TIF) surgery
No. patients 37
Female 21 (57%)
Age (range) (years) 58 (20–81)
C65 12 (34%)
BMI (range) (kg m
-2) 25.5 (15.9–36.1)
C35 2 (5%)
Primary GERD symptoms
Typical 12 (32%)
Atypical 25 (68%)
On PPI therapy 37 (100%)
Gastroesophageal reﬂux 37 (100%)
Hiatal hernia 25 (68%)
Reﬂux esophagitis 3 (8%)
Barrett’s short segment 1 (3%)
Values represent medians (range) or counts (%)
BMI body mass index, PPI proton pump inhibitor
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All TIF procedures were completed successfully. Median
operating time was 75 min (range = 45–110), and an
average of 17 (SD = 3) fasteners were used to create each
fundoplication. The TIF procedures reduced all 12 hiatal
hernias, and the postoperative endoscopic appearance of
the valves was consistent with a posterior partial fundo-
plication with a mean of 300 (range = 230–330) cir-
cumference around the esophagus and tight adherence to
the endoscope with fasteners placed 3–4 cm above the
Z-line (Fig. 3).
Patients were observed overnight and discharged the
following day in 35 cases. One patient required a 3-day
stay for pain control. Another patient was hospitalized for
pulmonary issues unrelated to the procedure.
Safety outcomes
Two complications directly related to the procedure were
observed.Onepatientpresentedonpostoperativeday(POD)
6 with a mediastinal abscess and underwent successful
laparoscopic drainage and takedown of the TIF fundopli-
cation, followed by Toupet fundoplication. This patient was
not included in the follow-up assessment. Technique mod-
iﬁcations related to these complications are described else-
where [25]. Traumatic dislodgement of the helical screw
was the etiology of the bleeding in the second patient in our
series. No patient reported side effects of gas-bloat or
increased ﬂatulence, and, in fact, bloating was reported less
often after the procedure than preoperatively (p\0.01).
Clinical outcomes
Subjective outcomes
Follow-up assessment was completed for 33 of the 37
treated patients at a median of 6 (range = 3–14) months.
Two patients were not able to complete either their ques-
tionnaires or endoscopy, one was lost to follow-up, and
another one was excluded due to postoperative complica-
tion and Toupet revision. Atypical symptoms were signif-
icantly improved as indicated by the reduction of mean
total RSI scores (mean = 12.9 ± 1.8 SEM, n = 32 vs.
22.8 ± 2.2 pre-TIF on PPIs, n = 23; p = 0.003; Table 2).
In 64% (14/22) of patients, RSI scores improved by more
than 50% compared to baseline on PPIs, and 52% (11/21)
had their scores normalized (Fig. 2, Table 2). Heartburn
was also improved signiﬁcantly as indicated by the
reduction of GERD-HRQL scores (mean = 5.0 ± 1.1
SEM, n = 32 vs. 15.3 ± 2.1 pre-TIF on PPIs, n = 21,
p = 0.002). GERD-HRQL scores were reduced by more
than 50% in 80% of patients and normalized in 50%.
Regurgitation scores were also signiﬁcantly reduced com-
pared to baseline on therapy (mean = 4.3 ± 1.2 SEM,
n = 32 vs. 11.2 ± 2.0 pre-TIF on PPIs, n = 21, p =
0.006). In 70% (14/20) of patients the regurgitation score
reduction exceeded 50%, and 62% (8/13) of patients had
normalized scores. Current health condition after TIF was
judged as satisfactory by 66% of patients, dissatisfactory
by 22%, and neither satisfactory nor dissatisfactory by
12% compared to 0, 81, and 19% of patients before
TIF, respectively (Table 2). Among 33 patients available
0%
20%
40%
60%
80%
100%
1. Hoarseness
2. Clearing throat **
3. Excess mucus **
4. Swallowing difficulty **
5. Coughing after meal
6. Breathing difficulty *
7. Troublesome cough
8. Lump in the throat *
9. Heartburn, …*
RSI Abnormal **
Pre-TIF Post-TIF
Fig. 2 Percentage of patients
who had abnormal Reﬂux
Symptom Index (RSI) scores
before esophagogastric transoral
incisionless fundoplication
(TIF) while taking PPIs (purple
ﬁeld) compared to that after TIF
while not taking PPIs (blue
ﬁeld). Total scores C13 with
any individual scores[2
(bothersome daily) were
indicative of troublesome
atypical symptoms. Signiﬁcant
differences indicated by * if
p\0.05 or ** if p B 0.01
(Fisher’s exact test)
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123at follow-up, 82% were completely off all GERD
medications.
Objective outcomes
Globally, all reﬂux characteristics were signiﬁcantly
improved following TIF in the 24 patients who underwent
pH testing off PPIs both preoperatively and at follow-up
and whose reﬂux characteristics on PPIs prior TIF were
elevated. Mean esophageal acid exposure (% time pH\4)
was signiﬁcantly (p = 0.003) reduced from 10.4 ± 1.7 to
5.2 ± 1.4% post-TIF (n = 18) and normalized in 61% of
patients (Fig. 4). Four patients had an increased ([5% over
preoperative value) amount of esophageal acid exposure
postoperatively. One of these improved symptomatically
and had an intact valve at postoperative endoscopy.
Another patient continued to have LPR symptoms and an
intact valve at postoperative endoscopy; no further treat-
ment or intervention was performed. Two patients had
recurrence of typical GERD symptoms and worsened acid
exposure and underwent revision to laparoscopic Nissen
(see below).
The average number of reﬂux episodes per 24-h testing
period was signiﬁcantly (p\0.001) reduced from
82.4 ± 7.2 to 20.8 ± 6.6 post-TIF and normalized in 89%
of patients (Fig. 5). DeMeester scores were signiﬁcantly
reduced from 37.1 ± 5.3 to 16.9 ± 4.0 and normalized in
56% of patients (Fig. 6). Most of TIF valves were tight and
had Hill grade of I (Table 3). Hiatal hernia was eliminated
in 9/9 cases (Table 3). Esophagitis was rarely observed
preoperatively as most patients were on antisecretory
medication at the time of or until 1 week prior to upper
endoscopy.
Global assessment
The global assessment of 24 patients who underwent pH
testing off PPIs both preoperatively and at follow-up and
whose reﬂux characteristics on PPIs prior TIF were elevated
revealed that TIF was effective in treating GERD in 75% of
them and among whom 54% were in complete remission
and had normal pH studies, and 21% were improved
symptomatically and physiologically and required no more
PPIs. The remaining 25% of the 24 patients had ongoing
GERD and were considered as failures.
Failures and revisions
Among the 37 patients enrolled, 5 (13.5%) underwent
revision: two with the TIF procedure within 3 and
6 months following the procedure, respectively, and three
with laparoscopic Nissen fundoplication after 4 (n = 1)
and 6 (n = 2) months. Laparoscopic revision from a failed
TIF to a Nissen fundoplication was relatively straightfor-
ward in these three patients. Failures were associated with
severe postoperative nausea and retching and severe
coughing, and, in one patient (BMI = 34), with a Belsey
fat pad that at laparoscopic reoperation was lipomatous and
prevented fusion of the fundus to the esophagus. Resolu-
tion of symptoms and normalization of acid exposure was
observed in four (80%) patients who had had a previous
Nissen procedure that was loose but without intrathoracic
wrap migration. The one failure was the patient with a prior
Toupet fundoplication.
Fig. 3 Retroﬂex view of the gastroesophageal junction before (top),
immediately after (middle), and at 6 months after (bottom) esophag-
ogastric transoral incisionless fundoplication (TIF) surgery
1980 Surg Endosc (2011) 25:1975–1984
123Discussion
The most important goals of any GERD treatment are
symptom control, prevention of GERD-related complica-
tions, and healing of esophagitis [34]. Although PPIs are
very effective in healing esophagitis, a signiﬁcant pro-
portion of patients continue to be symptomatic. Frequently,
these symptoms are laryngopharyngeal in nature. In addi-
tion, PPIs do not prevent nonacid reﬂux, which has been
imputed as the cause of GERD-related complications such
as asthma, aspiration pneumonia, or cough [35, 36]. Tra-
ditional surgical therapy for GERD, whether laparoscopic
or open, has been demonstrated to be effective in the
treatment of GERD refractory to medical therapy [37].
However, traditional fundoplication creates a super-com-
petent valve, which limits the ability to vent air and to
vomit and leads to side effects of dysphagia, bloating,
nausea, and meteorism in some patients. The super-com-
petent nature of the valve and concomitant side effects
have been a major limiting factor in the acceptance of
fundoplication by many patients and gastroenterologists.
Consider the following American Gastroenterological
Association medical position statement on the manage-
ment of GERD regarding antireﬂux surgery [2]: ‘‘The
potential beneﬁts of antireﬂux surgery should be weighed
against the deleterious effect of new symptoms consequent
from surgery, particularly dysphagia, ﬂatulence, an
inability to belch, and postsurgery bowel symptoms.’’ With
failures of both current medication regimens and tradi-
tional antireﬂux surgery, there is need for a therapy that
would treat medically refractory GERD symptoms without
the risks and side effects of traditional surgery. Such a
therapy could be acceptable, even if it had a more limited
success rate than the current modalities. Because no single-
treatment regimen is completely successful, GERD should
be considered a chronic condition that requires chronic
management and multimodality therapy, much like cardiac
disease [38].
Table 2 Reﬂux Symptom Index (RSI), GERD Health-related Quality of Life (GERD-HRQL), and regurgitation scores before esophagogastric
transoral incisionless fundoplication (TIF) surgery while on PPIs and at a median 6 (3–14) months after surgery
Pre-TIF on PPIs Post-TIF off PPIs p value
RSI scores
Median (range) 25 (5–38) n = 23 10 (0–39) n = 32 0.002
Mean (SEM) 22.8 (2.2) n = 23 12.9 (1.8) n = 32 0.003
n (%) abnormal
a 20/23 (87%) 11/32 (34%) \0.001
n (%) improved by C50%
b 14/22 (64%)
n (%) normalized
c 11/21 (52%)
GERD-HRQL scores
Median (range) 16 (0–29) n = 21 4 (0–27) n = 32 0.001
Mean (SEM) 15.3 (2.1) n = 21 5.0 (1.1) n = 32 0.002
n (%) abnormal
a 17 (81%) 13 (41%) \0.001
n (%) improved by C50%
b 16/20 (80%)
n (%) normalized
d 10/20 (50%)
Regurgitation scores
Median (range) 10 (0–26) n = 21 1 (0–25) n = 32 0.005
Mean (SEM) 11.2 (2.0) n = 21 4.3 (1.2) n = 32 0.006
n (%) abnormal
a 11/21 (52%) 6/32 (19%) 0.016
n (%) improved by C50%
b 14/20 (70%)
n (%) normalized
d 8/13 (62%)
Satisfaction index
e
n (%) satisﬁed 0/23 (0%) 21/32 (66%) \0.001
n (%) neutral 4/23 (19%) 4/32 (12%) \0.001
n (%) dissatisﬁed 17/23 (81%) 7/32 (22%) \0.001
p values\0.05 indicate signiﬁcant differences between medians (Mann–Whitney U test), means (paired t test), and ratios (Fisher’s exact test)
a Abnormal if any individual score[2
b Compared to baseline on PPIs
c Normalized RSI score deﬁned by a total score of B13 with each question evaluated as eliminated or rare (score B2)
d Normalized if none of the abnormal scores at baseline is[2 at follow-up
e Satisfaction index determined using GERD-HRQL indicates patient satisfaction with current health condition
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life by controlling reﬂux without creating side effects,
various transoral methods of restoring gastroesophageal
valve competence have been tried with varying degrees of
success [39–42]. Until recently, transoral procedures were
limited to gastrogastric plication or attempts to decrease the
compliance of the gastroesophageal valve. The EsophyX
device enables creation of full-thickness esophagogastric
plication transorally and is currently the only device
commercially available that does so.
With our technique the device was used to create not
merely a longitudinal esophagogastric fundoplication (the
so-called TIF 2), but a rotational and longitudinal esoph-
agogastric fundoplication. The phrenoesophageal mem-
branes are left intact and small hiatal hernias are reduced.
Based on limited experience, performance of a laparo-
scopic fundoplication in the case of failure is not signiﬁ-
cantly more complicated than performance of a primary
laparoscopic fundoplication. This retrospective study of
our ﬁrst 37 patients represents the results of our initial
learning curve both with the device and with the devel-
opment of this technique. Despite these potential limita-
tions, our results are signiﬁcant in terms of symptom
improvement and objective reﬂux control. Perhaps just as
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Fig. 4 Esophageal acid exposure (% time pH\4) before and
6 months after esophagogastric transoral incisionless fundoplication
(TIF) in patients with abnormal values at baseline either after
discontinuation of proton pump inhibitors (PPIs) for 7 days (n = 13)
or while on therapy (n = 5, highlighted in purple). Mean acid
exposure (black trend line with SEM error bars) was signiﬁcantly
reduced (n = 18, p = 0.003, paired t test)
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Fig. 5 Number of acid reﬂux episodes (pH\4) per 24 h before and
6 months after esophagogastric transoral incisionless fundoplication
(TIF) in patients with abnormal values at baseline either after
discontinuation of proton pump inhibitors (PPIs) for 7 days (n = 14)
or while on therapy (n = 4, highlighted in purple). Mean number of
episodes (black trend line with SEM bars) was signiﬁcantly reduced
(p\0.001, paired t test)
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Fig. 6 DeMeester scores before and 6 months after esophagogastric
transoral incisionless fundoplication (TIF) in patients with abnormal
values at baseline either after discontinuation of proton pump
inhibitors (PPIs) for 7 days (n = 16) or while on therapy (n = 2,
highlighted in purple). Mean score (black trend line with SEM bars)
was signiﬁcantly reduced (p\0.001, paired t test)
Table 3 Endoscopic evaluation before and 6 (3–14) months after
esophagogastric transoral incisionless fundoplication (TIF)
Pre-TIF 6-mo Post-TIF
Hill grade n = 36 n = 32
Median size (cm) 2 (2–3) 1 (1–3)
Grade I 0 (0%) 19 (59%)
Grade II 29 (81%) 9 (28%)
Grade III 7 (19%) 4 (13%)
Grade IV 0 (0%) 0 (0%)
Reduced to grade II – 2 (6%)
Normalized to grade I – 19 (59%)
p value for grade change \0.001
Hiatal hernia height n = 36 n = 29
None 24 (67%) 28/29 (97%)
C2 cm 12 (33%) 1 (3%)
Eliminated if B1 cm – 9/9 (100%)
Worsened – 1/24 (4%)
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123important, we have not observed any of the side effects
seen with traditional fundoplications.
The utilization of postoperative pH-metry as an end
point in this study should be understood in the context of
the treatment goals mentioned above, which do not include
normalization of acid exposure [43, 44]. Most acid reﬂux
events in GERD patients are asymptomatic [45]. Eighteen
to 30% of patients who have met treatment goals of
symptom control and healing of esophagitis with PPI
therapy have abnormal amounts of esophageal acid expo-
sure [46]. We chose to measure reﬂux postoperatively with
the intent to demonstrate that the TIF procedure produces
objectively identiﬁable changes in the amount of esopha-
geal acid exposure that correlate with symptom improve-
ment. Utilization of a telemetry capsule pH probe was
favored over transnasal impedance testing because of
patient acceptance, even though it did not provide us with
information on nonacid reﬂux events [47, 48]. In our
research protocol we deﬁned pH-metric success by nor-
malization of one or more of the acid reﬂux characteristics
such as acid exposure, number of reﬂuxates, or DeMeester
score. By these protocol-speciﬁc pH-metric standards, the
TIF procedure was successful in up to 89% of patients.
Limitations of this study include its retrospective nature
of baseline data collection, with associated incomplete data
set for all patients, and the 6-month duration of follow-up.
In addition, this study represents our initial learning curve
not only with the device but with the evolution of the
rotational-longitudinal esophagogastric fundoplication
technique. We are currently conducting a prospective study
to address these limitations; but we believe this current
study’s results to be signiﬁcant enough to report. This
technique should not be considered experimental, a
position supported by position statements from the Society
of American Gastrointestinal and Endoscopic Surgeons
(SAGES) [49] and the American Society of General Sur-
geons (ASGS) [50].
Conclusion
The creation of a radial and longitudinal esophagogastric
fundoplication using the EsophyX device signiﬁcantly
improved symptomatic outcomes in 64–80% of patients at
a median 6-month follow-up. TIF effectively controlled
reﬂux without patients developing any of the side effects of
traditional surgery. Postoperative recovery was rapid and
clinical outcomes were encouraging. Proper technique can
minimize the risk of complications. Transoral esophagog-
astric fundoplication has a role in the treatment of GERD.
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